{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    7,
    20,
    25,
    26,
    34,
    41,
    45,
    47,
    48,
    49,
    50,
    52,
    54
  ],
  "modelUsed": "gpt-5.2",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "SoA Table Footnote Link to Section 8",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Schedule of Activities (SoA)",
        "description": "Amendment summary notes added footnote text in Table 1 stating that procedures specific to screening sites (US only) are detailed in Section 8."
      },
      {
        "id": "ref_2",
        "name": "Amendment Summary Reference to Section 8",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8",
        "sectionTitle": "Study Assessments and Procedures",
        "description": "Amendment summary refers readers to Section 8 for details on screening-site-specific procedures (US only)."
      },
      {
        "id": "ref_3",
        "name": "COVID-19 Vaccine Risk Assessment Cross-Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2.3.1.1",
        "sectionTitle": "Coronavirus (SARS-CoV-2) Disease 2019",
        "description": "Text states COVID-19 vaccine risk/mitigation considerations; directs to Section 10.5."
      },
      {
        "id": "ref_4",
        "name": "Dose Modification Cross-Reference from Risk Table",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.6",
        "sectionTitle": "Dose Modification",
        "description": "Table 3 mitigation strategy repeatedly references dose modification/discontinuation in Section 6.6."
      },
      {
        "id": "ref_5",
        "name": "Adaptive Features Cross-Reference to Table 4",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.2",
        "sectionTitle": "Scientific Rationale for Study Design",
        "description": "Narrative states adaptive features and limits are described in Table 4."
      },
      {
        "id": "ref_6",
        "name": "Dose Modification Criteria Cross-Reference to Table 7",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.2",
        "sectionTitle": "Scientific Rationale for Study Design",
        "description": "Adaptive Protocol Features (Table 4) references Dose Modification criteria in Table 7."
      },
      {
        "id": "ref_7",
        "name": "Blood Donation Restriction Cross-Reference to Exclusion Criteria",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.2",
        "sectionTitle": "Exclusion Criteria",
        "description": "Lifestyle restriction table references screening exclusion relating to blood loss in excess of 500 mL in 60 days prior to screening (Section 5.2)."
      },
      {
        "id": "ref_8",
        "name": "Contraception Guidance Cross-Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.4",
        "sectionTitle": "Contraceptive Guidance and Collection of Pregnancy Information",
        "description": "Lifestyle restriction table directs to Section 10.4 for contraceptive methods and indicates restrictions end per Section 10.4."
      },
      {
        "id": "ref_9",
        "name": "Inclusion Criteria Cross-Reference from Lifestyle Table",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1",
        "sectionTitle": "Inclusion Criteria",
        "description": "Lifestyle restriction table states contraceptive start times vary by method (see Section 5.1 [inclusion criteria])."
      },
      {
        "id": "ref_10",
        "name": "Study Intervention Discontinuation Data Collection Cross-Reference to SoA",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.1",
        "sectionTitle": "Discontinuation of Study Intervention",
        "description": "Directs to Schedule of Activities (SoA, Section 1.3) for data/samples to be collected at discontinuation and follow-up."
      },
      {
        "id": "ref_11",
        "name": "Discontinuation and Follow-up Cross-Reference to Table 1",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.1",
        "sectionTitle": "Discontinuation of Study Intervention",
        "description": "Directs to SoA (Table 1) for samples and data at study intervention discontinuation and follow-up."
      },
      {
        "id": "ref_12",
        "name": "Discontinuation Criteria Cross-Reference to Dose Modification",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.1",
        "sectionTitle": "Discontinuation of Study Intervention",
        "description": "States discontinuation for abnormal liver function should be considered when Dose Modification criteria are met (Section 6.6)."
      },
      {
        "id": "ref_13",
        "name": "Pregnancy Discontinuation Cross-Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.2.6",
        "sectionTitle": "Pregnancy",
        "description": "Discontinuation criteria include pregnancy/planned pregnancy and direct to Section 8.2.6."
      },
      {
        "id": "ref_14",
        "name": "Participant Withdrawal Visit Cross-Reference to SoA",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.2",
        "sectionTitle": "Participant Discontinuation/Withdrawal From the Study",
        "description": "Early discontinuation visit and required follow-up are directed to the SoA; explicitly references SoA (Section 1.3)."
      },
      {
        "id": "ref_15",
        "name": "ECG Timing Cross-Reference to SoA",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.2.3",
        "sectionTitle": "Electrocardiograms",
        "description": "States triplicate ECGs will be conducted as outlined in the SoA (see Section 1.3)."
      },
      {
        "id": "ref_16",
        "name": "ECG QTc Withdrawal Criteria Cross-Reference to Section 7",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.2.3",
        "sectionTitle": "Electrocardiograms",
        "description": "Directs readers to Section 7 for QTc withdrawal criteria and additional QTc readings."
      },
      {
        "id": "ref_17",
        "name": "Clinical Labs Test List Cross-Reference to Section 10.2 and SoA",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.2.4",
        "sectionTitle": "Clinical Safety Laboratory Assessments",
        "description": "Directs to Section 10.2 for list of tests and to SoA (Section 1.3) for timing/frequency."
      },
      {
        "id": "ref_18",
        "name": "Protocol-Required Labs Cross-Reference to Section 10.2",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.2.4",
        "sectionTitle": "Clinical Safety Laboratory Assessments",
        "description": "States all protocol-required laboratory assessments are as defined in Section 10.2."
      },
      {
        "id": "ref_19",
        "name": "AE Follow-Up Cross-Reference to Section 7",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.3",
        "sectionTitle": "Adverse Events and Serious Adverse Events",
        "description": "States follow-up responsibility for AEs that caused discontinuation of study intervention and references Section 7."
      },
      {
        "id": "ref_20",
        "name": "AE/SAE Procedures Cross-Reference to Section 10.3",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.3",
        "sectionTitle": "Adverse Events and Serious Adverse Events",
        "description": "States that procedures for recording/evaluating/follow-up/reporting AEs and SAEs are outlined in Section 10.3."
      },
      {
        "id": "ref_21",
        "name": "SAE Reporting Timeframe Cross-Reference to Section 10.3",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.3.1",
        "sectionTitle": "Time Period and Frequency for Collecting AE and SAE Information",
        "description": "States SAEs reported within 24 hours as indicated in Section 10.3."
      },
      {
        "id": "ref_22",
        "name": "Detecting/Assessing Causality Cross-Reference to Section 10.3",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.3.2",
        "sectionTitle": "Method of Detecting AEs and SAEs",
        "description": "Refers to Section 10.3 for recording, evaluating, causality assessment, and SAE report procedures."
      },
      {
        "id": "ref_23",
        "name": "Lost to Follow-up Definition Cross-Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.3",
        "sectionTitle": "Lost to Follow-up",
        "description": "AE/SAE follow-up section references lost to follow-up definition in Section 7.3."
      },
      {
        "id": "ref_24",
        "name": "Further Follow-up Procedures Cross-Reference to Section 10.3",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.3.3",
        "sectionTitle": "Follow-up of AEs and SAEs",
        "description": "States further information on follow-up procedures is provided in Section 10.3."
      },
      {
        "id": "ref_25",
        "name": "PK Sampling Cross-Reference to SoA Table 1",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.5",
        "sectionTitle": "Pharmacokinetics",
        "description": "States whole blood sampling is specified in SoA (Table 1)."
      },
      {
        "id": "ref_26",
        "name": "PK/PD Copper/Molybdenum Measurements Cross-Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.1.1",
        "sectionTitle": "Copper and Molybdenum Balance Measurements",
        "description": "Pharmacokinetics section directs to Section 8.1.1 for details of molybdenum measured in food, drinks, urine, and feces."
      },
      {
        "id": "ref_27",
        "name": "PD Sampling Cross-Reference to SoA Table 1",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.6",
        "sectionTitle": "Pharmacodynamics",
        "description": "States blood samples collected as described in SoA (Table 1)."
      },
      {
        "id": "ref_28",
        "name": "Biomarkers Cross-References to Sections 8.6 and 8.1.1",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.8",
        "sectionTitle": "Biomarkers",
        "description": "Directs readers to Section 8.6 for plasma copper-related measures and to Section 8.1.1 for copper measured in food/drink/urine/feces."
      },
      {
        "id": "ref_29",
        "name": "Biobanked Sample Genetics Cross-Reference to Section 8.7",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.3.6",
        "sectionTitle": "Retained and Biobanked Sample",
        "description": "States sample will not be used for genetic testing and references Section 8.7."
      },
      {
        "id": "ref_30",
        "name": "Analysis Populations Cross-Reference to Table 8",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.3",
        "sectionTitle": "Populations for Analyses",
        "description": "States population sets used for analysis are defined in Table 8."
      },
      {
        "id": "ref_31",
        "name": "ECG Parameters Cross-Reference to SoA Table 1 in Statistical Analyses",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.4",
        "sectionTitle": "Statistical Analyses",
        "description": "States ECG parameters measured at specified time points as per SoA (Table 1)."
      },
      {
        "id": "ref_32",
        "name": "Investigator’s Brochure References",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2.3.1",
        "sectionTitle": "Risk Assessment (Table 3 context)",
        "description": "Table 3 repeatedly directs to 'see the IB' / 'refer to the current IB' for supporting data."
      },
      {
        "id": "ref_33",
        "name": "COVID-19 Vaccine Risk Table Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.5",
        "sectionTitle": "COVID-19 Vaccine Risk Assessment",
        "description": "List of tables includes Table 10 'Potential Risks and Mitigation Measures due to COVID-19 Vaccine' which corresponds to Section 10.5."
      },
      {
        "id": "ref_34",
        "name": "Protocol Amendment History Section Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.7",
        "sectionTitle": "Protocol Amendment History",
        "description": "Table of contents indicates a dedicated section for amendment history (Section 10.7)."
      },
      {
        "id": "ref_35",
        "name": "Table and Figure Internal References (List of Tables/Figures)",
        "instanceType": "DocumentContentReference",
        "description": "Document includes internal references to Table 1-11 and Figure 1 by title and page number in the List of Tables/Figures."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Table 3 abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; IB = Investigator’s Brochure; PK = pharmacokinetics; WD = Wilson disease.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "2.3.1 Risk Assessment / Table 3",
        "pageNumber": 21
      },
      {
        "id": "annot_2",
        "text": "Catheter/cannula comment: a catheter may not be left in place for longer than 72 hours and should be flushed a minimum of every 8 hours.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "2.3.1 Risk Assessment / Table 3 (Study Procedures row)",
        "pageNumber": 21
      },
      {
        "id": "annot_3",
        "text": "Lifestyle restrictions table abbreviations: CRF = case report form; CRU = clinical research unit; EOS = End of Study; SoA = Schedule of Activities.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "5.3 Lifestyle Considerations (restrictions table excerpt)",
        "pageNumber": 35
      },
      {
        "id": "annot_4",
        "text": "Vital signs: if abnormal per inclusion/exclusion criteria, 2 additional measurements will be made and the average of 3 recorded in the CRF and used for eligibility.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "8.2.2 Vital Signs (text preceding 8.2.3 header)",
        "pageNumber": 46
      },
      {
        "id": "annot_5",
        "text": "Pharmacokinetics sampling window: samples collected within ±10% or 30 min (whichever is less) of scheduled time will not be considered a protocol deviation.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "8.5 Pharmacokinetics",
        "pageNumber": 49
      },
      {
        "id": "annot_6",
        "text": "Retained/biobanked sample: single predose serum sample retained on site and discarded after clinical study report; not used for genetic testing.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "8.3.6 Retained and Biobanked Sample",
        "pageNumber": 49
      },
      {
        "id": "annot_7",
        "text": "Excess/additional whole blood samples may be stored for up to 5 years and used for PD/biomarker research; not for genetic analyses (RNA/DNA).",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "8.5 Pharmacokinetics",
        "pageNumber": 50
      },
      {
        "id": "annot_8",
        "text": "Population table abbreviations: ICF = informed consent form; PD = pharmacodynamic; PK = pharmacokinetic.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.3 Populations for Analyses / Table 8",
        "pageNumber": 51
      },
      {
        "id": "annot_9",
        "text": "PK parameter note: Day 28 concentration-time profiles after last 15 mg dose will be extrapolated to Day 29 (0-24 hr) and subtracted from observed Day 29 profiles after first 30 mg dose (adjustment for accumulation calculations).",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.4.4 Pharmacokinetic, Pharmacodynamic, and Biomarker Analyses",
        "pageNumber": 53
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "Amendment 3.1 (US)",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2022-03-18",
        "description": "Protocol Amendment 3.1 (US) dated 18 Mar 2022 for protocol ALXN1840-WD-204.",
        "amendmentNumber": "3.1 (US)"
      },
      {
        "id": "ver_2",
        "versionNumber": "Original Protocol",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-05-12",
        "description": "Original protocol approval date listed on title page."
      },
      {
        "id": "ver_3",
        "versionNumber": "Amendment 1",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-08-18",
        "description": "Amendment 1 approval date listed on title page.",
        "amendmentNumber": "1"
      },
      {
        "id": "ver_4",
        "versionNumber": "Amendment 2",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-03-19",
        "description": "Amendment 2 approval date listed on title page.",
        "amendmentNumber": "2"
      },
      {
        "id": "ver_5",
        "versionNumber": "Amendment 3",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-08-31",
        "description": "Amendment 3 approval date listed on title page.",
        "amendmentNumber": "3"
      }
    ],
    "summary": {
      "referenceCount": 35,
      "annotationCount": 9,
      "versionCount": 5
    }
  }
}